Platinum-resistant ovarian cancer has historically been difficult to treat, but new trials are exploring a new class of drugs that researchers find encouraging.
In this video, Dr. Kari Hacker, a gynecologic oncologist at the UNC Lineberger Comprehensive Cancer Center explains why results from the ROSELLA trial are meaningful for patients with platinum-resistant ovarian cancer.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.
